Cassorla received his MD from the University of Chile. He has authored numerous chapters in pediatric endocrinology, authored or co-authored over 200 original articles in peer reviewed journals, and has presented over 300 abstracts at scientific meetings. Cassorla served as Senior Investigator at the Developmental Endocrinology Branch of the National Institute of Child Health and Human Development, rising to the position of Clinical Director of this Institute in 1990. is currently Chief of Pediatric Endocrinology at the Institute of Maternal and Child Research of the University of Chile, a position he has held since 1993. Cassorla and Tansey will be available to answer questions following their formal presentations.įernando Cassorla, M.D. The event will feature presentations by KOLs in the field of pediatric endocrinology, Fernando Cassorla, MD, Chief of Pediatric Endocrinology, University of Chile, and Michael Tansey, MD, Clinical Professor of Pediatrics-Endocrinology and Diabetes, University of Iowa, Carver College of Medicine who will review interim data from our Phase 2 OraGrowtH210 and OraGrowtH212 Trials presented at ENDO. To register for the virtual KOL Event, please click through the link HERE.Virtual KOL Webinar – Wednesday, June 21, 2023, 11:00 AM – 12:00 PM EDT Title (Abstract 6014) – Growth Response of Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data, Michael Tansey, MD, Clinical Professor of Pediatrics-Endocrinology and Diabetes, University of Iowa, Carver College of Medicine.Title (Abstract 6273) – Dose Responsiveness of LUM-201 as Measured by Acute GH Response and IGF-1 and Annualized Height Velocity (AHV) Measured at 6 Months in the Interim Analysis of the OraGrowtH212 Study in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD), Fernando Cassorla, MD, Chief of Pediatric Endocrinology, University of Chile.Fernando Cassorla and Michael Tansey will review interim data evaluating oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the ENDO Meeting.ĮNDO Session OR21 – Update on Growth Disorders – Saturday, June 17, 2023, 3:30 – 5:00 PM CDT Lumos Pharma will host a virtual Key Opinion Leader (KOL) Webinar on June 21, 2023, 11:00 AM – 12 PM EDT where Drs. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that interim data from its OraGrowtH210 and OraGrowtH212 Trials will be reviewed in two oral presentations in Session OR21 – “Update on Growth Disorders” at the 2023 Annual Meeting of the Endocrine Society (ENDO), held in Chicago, Illinois, June 15-18, 2023. AUSTIN, Texas, (GLOBE NEWSWIRE) - Lumos Pharma, Inc.

Endo pharma hgh